Wednesday, Oct 14, 1987

Genentech Appoints Two Vice Presidents

South San Francisco, Calif. -- October 14, 1987 --

Genentech, Inc. announced today the appointment of John P. McLaughlin, vice president of government affairs and Nikolaus Kaubisch, Ph. D., vice president of business development.

McLaughlin, 36, will open an office for Genentech in Washington, D.C., where he will manage and expand the company¹s relationships on Capitol Hill and with various regulatory agencies. He joins Genentech from Royer, Shacknai & Mehle, a Washington, D.C. law firm where he was a partner and represented major pharmaceutical companies in government affairs.

Prior to this, McLaughlin was chief counsel to the House Energy and Commerce Subcommittee on Health and the Environment under the chairmanship of Rep. Henry A. Waxman (D-Los Angeles). Earlier, he served as counsel to the congressional subcommittee on Consumer Protection and Finance.

Kaubisch, 49, will be responsible for developing business relationships and agreements for Genentech with major corporate partners in the United States and abroad. he joins Genentech following a 16-year association with Boehringer Ingelheim, an international pharmaceutical company with headquarters in Ingelheim, West Germany.

Most recently, Kaubisch was vice president of research and development at Boehringer's Animal Health Inc. in St. Joseph, Missouri. There he directed all research and development activities, and was involved in the licensing of potential products and developing the strategic goals for the company's animal health business.

Earlier, he was corporate director of biochemistry at Boehringer Ingelheim Zentrale GmbH, Ingelheim, West Germany. There he coordinated worldwide biochemical activities including strategic planning and licensing for new business opportunities. Kaubisch also participated with Genentech in the establishment of a joint research institute in Vienna, Austria.

Genentech is a leading biotechnology company, focusing on the development, manufacture and marketing of pharmaceuticals produced by recombinant DNA technology.

# # #